Pharma News

Mentions of COVID-19 increased in the pharmaceutical industry in Q1 2023

Notably, COVID-19 was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of internet of things and governance, according to GlobalData.

Of the 50 leading companies in the pharmaceutical industry, BioNTech had the greatest increase in references for COVID-19 in Q1 2023, compared with the previous quarter. GlobalData identified 425 COVID-19-related sentences in the company’s filings – 35% of all sentences – and an increase of 900% in Q1 2023 compared with Q4 2022. Moderna’s mentions of COVID-19 rose by 100% to 280 and Pfizer’s by 100% to 169 and GSK’s by 100% to 141 and Eli Lilly and Co’s by 100% to 82.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for COVID-19 in Q1 2023 was 136.

To further understand GlobalData’s analysis on COVID-19 Cross-Sector Impact – Thematic Research, buy the report here.




Source link
#Mentions #COVID19 #increased #pharmaceutical #industry

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *